The valuation of the at-home blood collection devices market in 2024 is USD 93 million and this market is projected to reach USD 135 million by 2029, growing at a CAGR of 7.6% for the period from 2024 to 2029. High demand for at-home blood collection & microsampling devices is primarily on account of rising infectious diseases, chronic disorders, and lifestyle-related diseases.
Pathogenic microorganisms, a continuous danger to public health, have been a major threat and reason for many deathly infectious diseases causing outbreaks all over the world. Periodic monitoring of the viral load, antibodies, and other biomarkers is necessary in infectious diseases like HIV/AIDS, hepatitis, and new viral outbreaks to trace the progression of disease and effectiveness of treatment.
At-home blood collection devices are functional because they allow patients to collect blood samples within their environment, which reduces exposure in healthcare settings and allows for timely testing. The ease of use, privacy, and convenience are what drives this trend with the at-home blood collection device. Hence, due to increased infectious diseases cases, it should boost the growth and adoption of at-home blood collection kits.
“Fingerstick method segment has taken the larger portion of the at-home blood collection devices market, by collection method, during the forecast period.”
The at-home blood collection devices market can be segmented, based on the collection method, into fingerstick, push-button, and other sample collection methods. In 2023, the fingerstick method held the major share of the at-home blood collection devices market. Moreover, broad acceptance of fingerstick has been attributed to compliance with regulatory standards that ascertains additional safety and reliability for its use at home. This further consolidates its leading position on the market, as it can easily find its place within daily routine and allow regular health monitoring without professional interventions.
“Liquid samples segment accounted for the highest growth rate in the at-home blood collection devices market, by sample type, during the forecast period.”
The at-home blood collection devices market is further divided into liquid and dried samples based on the type of sample. Liquid blood samples are expected to grow at a higher CAGR in the at-home blood collection devices market as compared to dried samples, due to their superior performance for delivering accurate and immediate diagnostic results. Compared to a dried sample that is to be rehydrated and its problems of stability and degradation, liquid blood samples are way more reliable for the same purpose. Another reason blood in its liquid form is becoming more favored is that it is easier to collect enough volume to perform a wide variety of tests, and technological advances make this process easy to conduct and relatively painless. It is foreseen that liquid blood samples will continue to see rapid market growth due to their support for advanced testing methodologies and an increasing demand for real-time health monitoring.
“Asia Pacific: The fastest-growing region in at-home blood collection devices market.”
The worldwide market for at-home blood collection devices is categorized into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. The Asia Pacific region is poised to experience the most notable CAGR within the at-home blood collection devices market. Increasing collaborations between academic institutions, research organizations, and healthcare companies in the Asia Pacific region contribute to the advancement and commercialization of at-home blood collection devices technologies.
Rapid urbanization and growing disposable incomes have resulted in increased investments in healthcare and growing consumer demand for convenient health monitoring solutions.
The break-up of the profile of primary participants in the at-home blood collection devices market:
- By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 – 30%
- By Designation: C-level - 27%, D-level - 18%, and Others - 55%
- By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa- 4%
The key players in this market are Trajan Group Holdings Limited (Australia), Tasso, Inc. (US), YourBio Health, Inc. (US), A. Menarini Diagnostics (UK), R-Biopharm AG (Germany), Sussex Pathology Limited (UK), ImmunoServ (UK), Labonovum (Netherlands), Alpha Laboratories (UK), Lipomic Healthcare (India), Tri-Tech Forensics (US), RDA Spot Inc (Lithuania), Spot On Sciences (US), Capitainer (Sweden), PanoHealth (US), Lameditech (South Korea), Sara Healthcare (India), Owen Mumford Ltd (UK), RedDrop Dx, Inc. (US), AdvaCare Pharma (US), Naulakha Industries (India), and Phoenix Healthcare Solutions, LLC (US).
Research Coverage:
This research report categorizes the at-home blood collection devices market by product (Fingerstick Blood Collection Kits, DBS Collection Kits, Lancets, Other Products), by collection methods (Fingerstick Method, Push-button Method, Other Methods), by usability (Single-use Blood Collection Devices and Reusable Blood Collection Devices), by sample type (Dried Blood Samples and Liquid Blood Samples), by device type (Self-collection Devices and Professional Collection Devices), by application (Disease Diagnostics, Health Screening & Preventive Health, Clinical Trials & Research, Other Applications), and region (North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the at-home blood collection devices market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the at-home blood collection devices market. Competitive analysis of upcoming startups in the at-home blood collection devices market ecosystem is covered in this report.
Reasons To buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall at-home blood collection devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing burden of chronic disorders and lifestyle-related health conditions, Increasing prevalence of infectious diseases, Rising geriatric population and incidence of age-associated diseases, and Rising demand for painless devices and growing technological advancements), opportunities (Growth opportunities in emerging economies), restraints (Unregulated use of products for at-home blood collection and Pricing pressure owing to reimbursement cuts and budget constraints), and challenges (Inadequate access to microsampling devices in resource-limited areas) influencing the growth of the at-home blood collection devices market market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the at-home blood collection devices market market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the at-home blood collection devices market market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the at-home blood collection devices market market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Tasso, Inc. (US), Trajan Group Holdings Limited (Australia), YourBio Health, Inc. (US), Capitainer (Sweden), and A. Menarini Diagnostics s.r.l (UK).